Role of immunotherapy in gastrointestinal stromal tumors

Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, explores the use of immunotherapy in patients with gastrointestinal stromal tumors (GISTs), touching on strategies to increase the immunogenicity of the tumor microenvironment in order to improve the number of prolonged responses. Dr Heinrich also outlines the impact of tyrosine kinase inhibitors on responses to immune checkpoint blockade as evaluated in in vivo models. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.